Sub Banner Image

Summit Is in Talks for $15 Billion Partnership With AstraZeneca

Markets

Michelle F Davis, Dinesh Nair

·

July 3, 2025

·

Bloomberg

AstraZeneca Plc is discussing a partnership deal with Summit Therapeutics Inc. in which it could pay as much as $15 billion over time to license a lung-cancer drug, according to people familiar with the matter.

More from

Bloomberg

More

Markets

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.